Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pinatuzumab Vedotin||DCDT2980S||Pinatuzumab Vedotin (DCDT2980S) is an antibody drug conjugate (ADC) comprising a monoclonal antibody against CD22 attached to the drug monomethyl auristatin E, potentially resulting in increased death of CD22-positive tumor cells (PMID: 25708834, PMID: 30935953).|
|Polatuzumab vedotin-piiq||Polivy||ADC DCDS4501A|DCDS4501A|FCU 2711|RG7596|Ro 5541077-000|Polatuzumab Vedotin||Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody against B-cell antigen receptor complex-associated protein beta chain (CD79B) linked to monomethyl auristatin E (MMAE), which may deliver the cytotoxic MMAE to tumor cells over expressing CD79b (PMID: 26194424). Polivy (polatuzumab vedotin-piiq) is FDA-approved for use in combination with Treanda (bendamustine) and Rituxan (rituximab) in patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more prior therapies, and in combination with R-CHP in patients with untreated diffuse large B-cell lymphoma, not otherwise specified (NOS), or high-grade B-cell lymphoma with an IPI score of 2 or greater (FDA.gov).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 18||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01691898||Phase Ib/II||Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq||A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)||Completed||USA | ITA | FRA | DEU | CAN||1|